MAIA Biotechnology (MAIA) director granted 33,748 stock options

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. director Louie Ngar Yee received a grant of stock options for 33,748 shares of common stock. The options were granted on March 31, 2026 at an exercise price of $1.40 per share, vest 100% on the grant date, and are immediately exercisable.

Following this grant, he holds 33,748 stock options directly, which are scheduled to expire on March 31, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Louie Ngar Yee

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	33,748	$0.00	--

Holdings After Transaction: Stock Options — 33,748 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 33,748 options Exercise price: $1.40 per share Underlying shares: 33,748 shares +3 more

6 metrics

Options granted 33,748 options Stock options grant to director on March 31, 2026

Exercise price $1.40 per share Exercise price of granted stock options

Underlying shares 33,748 shares Common stock underlying the granted options

Total options after grant 33,748 options Total derivative holdings following the reported transaction

Grant vesting 100% on grant date Options vest fully on March 31, 2026

Expiration date March 31, 2036 Option term end date

Key Terms

Stock Options, 2021 Equity Incentive Plan, vest 100% on the date of the grant, exercisable

4 terms

Stock Options financial

"The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

2021 Equity Incentive Plan financial

"granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

vest 100% on the date of the grant financial

"representing the right to buy shares of common stock, vest 100% on the date of the grant"

exercisable financial

"vest 100% on the date of the grant and are exercisable beginning as of that date"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Louie Ngar Yee

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.4	03/31/2026		A		33,748		03/31/2026(1)	03/31/2036	Common Stock	33,748	$0	33,748	D

Explanation of Responses:

1. The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

	/s/ Louie Ngar Yee	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MAIA director Louie Ngar Yee report on this Form 4 for MAIA?

Louie Ngar Yee reported receiving a grant of 33,748 stock options. These options give him the right to buy MAIA common shares at $1.40 per share, reflecting a compensation-related equity award rather than an open-market purchase or sale.

How many MAIA Biotechnology stock options were granted to Louie Ngar Yee?

He was granted 33,748 stock options. Each option corresponds to one share of MAIA common stock, so the award represents potential future acquisition of 33,748 shares if he chooses to exercise the options at the stated exercise price.

What is the exercise price and term of the MAIA stock options granted to Louie Ngar Yee?

The options carry an exercise price of $1.40 per share and expire on March 31, 2036. This gives the director a long-dated right to purchase MAIA common stock at that fixed price during the option term.

When do Louie Ngar Yee’s MAIA stock options vest and become exercisable?

The options vest 100% on March 31, 2026, the grant date, and are exercisable beginning as of that date. This means the director can choose to exercise the full award immediately after grant, subject to plan and legal requirements.

How many MAIA stock options does Louie Ngar Yee hold after this reported grant?

After this grant, he holds 33,748 stock options directly. This total reflects the newly awarded options reported in the filing and represents his derivative position shown in this specific Form 4 report.